Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer-Reference-Cited by-同舟云学术

Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer

Published:2007 Issue:9 Volume:67 Page:933-942
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Noguchi Masanori,Yao Akihisa,Harada Mamoru,Nakashima Osamu,Komohara Yoshihiro,Yamada Satoko,Itoh Kyogo,Matsuoka Kei

Publisher

Wiley

Subject

Urology,Oncology

Reference26 articles.

1. The results of prostate carcinoma screening in the U.�S. As reflected in the surveillance, epidemiology, and end results program

2. PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY

3. PROSTATE CANCER IS HIGHLY PREDICTABLE: A PROGNOSTIC EQUATION BASED ON ALL MORPHOLOGICAL VARIABLES IN RADICAL PROSTATECTOMY SPECIMENS

4. , . Temporary combination therapy with Flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer. In: , , editors. Early stage prostate cancer: Diagnosis and choice of therapy. Amsterdam: Elsevier Biomedical Division; 1989.

5. Neoadjuvant Hormonal Deprivation in Patients with Locally Advanced Prostate Cancer

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer;Life;2023-07-01

2. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel;Oncology Reports;2020-11-11

3. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice;Scientific Reports;2020-10-14

4. Development of tumour peptide vaccines: From universalization to personalization;Scandinavian Journal of Immunology;2020-03-10

5. Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients;BMC Cancer;2018-10-16